Product Name:
Dok3-pY398
Product Number:
ab-pn508
Target Full Name: Docking protein 3
Target Alias: Dok-like protein; Dok3; DokL; Downstream of tyrosine kinase 3; FLJ22570; FLJ39939
Product Type Specific: DOK3 phosphosite-specific antibody
Antibody Code: PN508
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y398
Protein UniProt: Q7L591
Protein SigNET: Dok3
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Dok3 sequence peptide Cat. No.: PE-04AHH99
Antibody Immunogen Sequence: EHL(pY)ENL(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues E395 to L401; in the last quarter of the protein. The effect of Y398 phosphorylation is unclear. This is the major in vivo phosphorylation site in Dok3 (≥80 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus).
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rat | Mouse.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 55-60 kDa.
Antibody Specificity: Medium
Antibody Cross Reactivity: At high concentrations, this antibody starts to detected multiple proteins in A431 cells.
Related Product 1: DOK3 (395-401) pY398 antibody blocking peptide (Cat. No.: PE-04AHH99)
Related Product 2: DOK7 Y395 phosphorylation antibody (Cat. No.: AB-PN952)
Related Product 3: DOK7 Y405 phosphorylation antibody (Cat. No.: AB-PN953)
Scientific Background: Dok3 (Docking Protein 3) is a hematopoietic-specific adaptor/scaffolding protein that acts as a key negative regulator of immunoreceptor JNK signaling, including B-cell receptors (BCR) and Toll-like receptors (TLR). It acts as a molecular scaffold, recruiting phosphatases like INPP5D/SHIP1 to inhibit cellular activation and fine-tune immune responses. It features an N-terminal Pleckstrin Homology (PH) domain, a central Phosphotyrosine Binding (PTB) domain, and a C-terminal proline-rich region, often interacting with Grb2. It is highly expressed in hematopoietic tissues, such as the spleen and bone marrow, in B cells, macrophages, and neutrophils. It limits B-cell receptor signaling and controls plasma cell differentiation, with Dok3 deficiency leading to increased germinal center B cells. It restrains neutrophil production of calprotectin and protects against intestinal inflammation asociated with colitis. Upon phosphorylation, it binds to inhibitory molecules such as SHIP1 (INPP5D) and CSK. It acts as a scaffold that gathers these molecules to dampen immunoreceptor signalling. It protects against inflammatory bowel disease by regulating colonic neutrophils and is implicated in microglia-mediated neuropathic pain. It acts as a tumour suppressor in lung cancer and regulates immune cell infiltration in gliomas. Reduced expression of Dok3 is linked to poor prognosis in certain cancers, such as renal clear cell carcinoma. It is also involved in colorectal adenocarcinoma and glioma, where it may influence immune infiltration. This description may include information annotated by UniProt and/or Google AI.